A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma

Trial Profile

A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs F16 IL2 fusion protein (Primary) ; Paclitaxel
  • Indications Merkel cell carcinoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms IMMOMEC
  • Sponsors Philogen
  • Most Recent Events

    • 08 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top